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18.5 mol/L) compared with patients not receiving it (8.3 Ϯ Background. High-efficiency hemodialysis may induce a 9.8 mol/L, P Ͻ 0.05). However, at 12 months, no difference deficiency in hydrosoluble vitamins. Supplementation with between both subgroups persisted. When considering the dif-B-complex vitamins has been shown to lower serum homocysteine concentrations in several groups, but relatively few studferent genotypes, tHcy at baseline tended to be higher for TT ies have concerned hemodialysis patients. Our objectives were than CT and CC (39.8 Ϯ 30.9 vs. 31.4 Ϯ 10.5 vs. 31.6 Ϯ 11.8 to determine the status in B-complex vitamins in a large cohort mol/L) and decreased to respective values of 21.1 Ϯ 6.9 versus of unsupplemented hemodialysis patients and to assess the 21.4 Ϯ 6.1 versus 22.2 Ϯ 5.9 mol/L at 12 months. The impact effects of supplementation with hydrosoluble vitamins on seof the addition of folic acid to DiaVite appeared particularly rum homocysteine over one year. significant in TT patients at six months.
Methods. Serum total homocysteine (tHcy), vitamin B 12 , fo-
Conclusions.
(1) Hyperhomocysteinemia was present in late, pyridoxal-5Ј-phosphate (P-5Ј-P; the active moiety of vita-100% of our hemodialysis patients. (2) Nearly 40% of our min B 6 ), as well as red blood cell folate concentrations, were unsupplemented hemodialysis patients were deficient in vitameasured in 168 chronic dialysis patients on three times weekly min B 6 . (3) Supplementation with DiaVite has resulted in high-efficiency hemodialysis and not supplemented with hydrosignificant tHcy reductions for all three genotypes. (4) The soluble vitamins. Their methylenetetrahydrofolate reductase impact of the proposed supplementation protocol was found C677T (MTHFR) genotypes were also determined (homozyafter six months and was maintained, but did not increase gotes TT, heterozygotes CT, without mutation CC). All infurther after 12 months of the same regimen. (5) The addition volved patients were then supplemented with hydrosoluble of intravenous folic acid has been associated with a more provitamins (once daily by mouth, DiaVite; R&D Laboratories, nounced decrease in tHcy in TT patients. Minneapolis, MN, USA), and half of them were randomized to receive in addition 10 mg intravenously of folic acid posthemodialysis (30 mg intravenously per week). Serum tHcy was Hyperhomocysteinemia is now recognized as an indemonitored after 6 and 12 months of supplementation in the 140 and 128 patients available for follow-up. pendent risk factor for atherosclerotic cardiovascular disResults. At baseline, serum and red blood cell folate conceneases in the general population [1] [2] [3] [4] [5] . There is a higher trations were within normal limits in all patients except for prevalence of hyperhomocysteinemia in end-stage renal two with borderline serum folate (mean values of 21 Ϯ 8 and disease (ESRD) patients who are predialysis and on dial-1195 Ϯ 454 nmol/L), whereas serum vitamin B 12 and P-5Ј-P were below normal in 11 and 65 patients, respectively (mean ysis [6, 7] , as well as in renal transplant patients [8, 9] . In both populations, the increased incidence of atheropatients). Initial tHcy levels were increased in all patients sclerotic vascular disease has been shown to correlate (mean 33.3 Ϯ 16.6 for a normal below 11.8 Ϯ 1.5 mol/L); with the level of serum homocysteine [9-13]. Moreover, tHcy significantly decreased to 23.5 Ϯ 7.6 mol/L after six ESRD patients have serum total homocysteine (tHcy) months (P Ͻ 0.0001 vs. baseline) and to 21.7 Ϯ 6.1 mol/L after 12 months (P Ͻ 0.0001 vs. baseline) for the entire group, values twofold to threefold higher than those of agebut was normalized in only four patients at 12 months. After matched controls with normal renal function [14, 15] .
Recognized causes of hyperhomocysteinemia include deficiencies or mutation of enzymes involved in the me-alone or in combination, has been successful in reducing France) at a blood flow rate of 350 to 450 mL/min and a dialysate flow rate of 500 to 600 mL/min. homocysteine concentrations to various degrees in different subgroups of patients [16] [17] [18] [19] [20] [21] [22] . Although a reducBlood sampling and vitamin supplementation tion in serum homocysteine has been associated with None of the involved patients were receiving vitamin fewer atherothrombotic events in patients afflicted by supplementation at study entry, since it had not been a the genetic disorder homocystinuria [23, 24] , its benefit routine practice in our unit for more than five years. At remains to be proven for milder degrees of hyperhomothe beginning of the study, baseline values of serum cysteinemia such as that which occurs in chronic renal tHcy, serum vitamin B 12 , serum folate, serum pyridoxalfailure patients.
5Ј-phosphate (P-5Ј-P, the active moiety of vitamin B 6 ), On the other hand, patients on hemodialysis are at and red blood cell folate were measured in all patients. risk for deficiency in hydrosoluble vitamins as a conseThereafter, all patients were supplemented with hyquence of either poor intake, decreased absorption, aldrosoluble vitamins orally (DiaVite once daily taken tered metabolism, and/or dialysis-induced losses [25] [26] [27] .
by mouth; R&D Laboratories, Marina del Rey, CA, High-flux hemodialysis may further decrease serum con-USA; note that Nephro-Vite is marketed in Canada as centrations of hydrosoluble vitamins [27, 28] , while DiaVite). Moreover, half of the patients were randomerythropoietin therapy may precipitate folate and vitaized to receive an additional 10 mg of folic acid intravemin B 12 deficiencies [29, 30] . Most of the studies that nously posthemodialysis, and hence were administered have addressed the impact of vitamin supplementation 30 mg intravenously per week. Measurements of serum on homocysteine levels in ESRD patients were pertHcy, folate, vitamin B 12 , and P-5Ј-P were repeated after formed over short time periods [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , with only one 6 and 12 months of supplementation. The MTHFR genorecent study reporting results over one year [41] . Moretype status of our patients was also determined. over, chronic renal disease is associated with a relative DiaVite is a hydrosoluble multivitamin formulation resistance to the lowering effects of low-dose folate supcontaining per capsule 1 mg of folic acid, 10 mg of pyriplementation on homocysteine [36, 42] . Whereas 1 to 5 doxine (vitamin B 6 ), and 6 g of cobalamin (vitamin mg/day of folic acid may normalize plasma homocysteine B 12 ). It also contains ascorbic acid (vitamin C, 60 mg), in moderately hyperhomocysteinemic individuals with thiamine (vitamin B 1 , 1.5 mg), riboflavin (vitamin B 2 , 1.7 normal renal function, a similar effect has not been obmg), nicotinic acid (20 mg), panthothenic acid (10 mg), served in ESRD patients. Hence, the optimal dose as and biotin (300 g). well as the ultimate benefits remain to be clearly demonstrated in chronic dialysis patients.
Homocysteine assay The purpose of the present study was to assess the Total homocysteine serum concentrations (comprising effects of enteral (Ϯ parenteral) supplementation with both free and protein-bound forms) were obtained predihydrosoluble vitamins on serum homocysteine concentraalysis. After drawing, blood was placed immediately on tions in a large cohort of chronic hemodialysis patients ice, and serum was separated promptly by centrifugation over a one year interval. Concomitantly, the methyleneat 3000 r.p.m. The serum fraction was removed and then tetrahydrofolate reductase (MTHFR) genotype of our stored at Ϫ80ЊC until assayed. Total serum homocysteine group of patients was determined, since a mutation of this levels were measured using high-performance liquid enzyme is commonly related to hyperhomocysteinemia chromatography (HPLC) with fluorometric detection as [43] . This allowed us to evaluate the impact of supplerecently described [44] . This method allows the simultamentation with hydrosoluble vitamins for the different neous measurement of other thiols found in serum (cysgenotypes of this enzyme prevailing in our hemodialysis teine, cysteinylglycine, and glutathion). Normal values population.
are below 11.8 Ϯ 1.5 mol/L for males and below 10.9 Ϯ 2.0 mol/L for females.
METHODS

Serum measures of B-complex vitamins Patients and hemodialysis technique
Serum folate and vitamin B 12 were determined by imOne hundred sixty-eight chronic dialysis patients were munochemiluminescence (Access Immunoassay Instruinitially enrolled in the study after informed consent. All ments, Beckman, Mississauga, Canada). Normal values patients were on hemodialysis at the beginning of the for folate and vitamin B 12 were Ͼ10 nmol/L and 190 to study in May 1998, with a regimen including three times 730 pmol/L, respectively, whereas values compatible weekly sessions (3.5 to 4 hours each) using high-effiwith frank deficiencies are Ͻ7 nmol/L and Ͻ150 pmol/L, ciency reused dialyzers (CT190, Dicea170, Tricea210;
respectively. P-5Ј-P, the active moiety of vitamin B 6 , was Baxter, McGaw Park, IL, USA; or F8, F80; Fresenius, measured by radioenzymatic assay (vitamin B 6 3 H REA; Bü hlmann Laboratories, American Laboratory Products, Bad Homburg, Germany; or Filtral 20, Hospal, Lyon, Windham, NH, USA); normal values for P-5Ј-P were between 11.5 and 179.3 nmol/L (as reported by the manufacturer). Red blood cell folate was obtained using the to peritoneal dialysis (7), renal transplantation (7), and same method as for serum folate but applied after cell transfer to another dialysis center (2) . At 12 months, 12 lysis. Normal values were between 375 and 2500 nmol/L, more patients (7%) were lost at follow-up as a conseand values compatible with deficiency were Ͻ125 nmol/L. quence of death (7), switch to peritoneal dialysis (2), renal transplantation (2), and transfer to another center MTHFR genotype determination (1) . None were withdrawn from the study for side effects of vitamin supplementation. All patients were included The polymerase chain reaction primers for the ampliin the baseline analysis, and therefore, 140 patients refication of the MTHFR mutation have been described mained in the analysis at 6 months and 128 patients at elsewhere [45] . If the MTHFR mutation is present, HinfI 12 months. digests the 198 bp fragment into a 175 bp and a 23 bp Table 2 shows the evolution of serum folate, vitamin fragments. Analyzing the fragments in 2.5% polyacryl-B 12 , P-5Ј-P, tHcy, and red blood cell folate concentrations amide gel electrophoresis allows the determination of over the study period in all patients involved in the study the length of the fragments. and by subgroups receiving or not receiving folic acid. In the next section, results are presented as mean Ϯ At baseline, serum and red blood cell folate levels were SD. Statistics applied were analysis of variance or paired within normal limits in all unsupplemented patients, exor unpaired Student's t-test, where appropriate. cept for two patients having borderline serum folate (above 7 but below 10 nmol/L). Although the mean value RESULTS of serum vitamin B 12 was also within normal limits (326.9 Ϯ At baseline, there were 99 males and 69 females with 215.2 pmol/L), 11 patients (6%) were deficient, having a mean age of 60.8 Ϯ 7.2 years; they had been on hemodivalues below 150 pmol/L at baseline. P-5Ј-P was below alysis for an average of 3.2 Ϯ 0.9 years. In the preceding normal in a large proportion of patients at the start (65 months, their mean Kt/V and nPCR (normalized protein patients or 39%), with initial mean and median values catabolic rate) were, respectively, 1.68 Ϯ 0.06 and 0.95 Ϯ of 19.1 Ϯ 15.6 and 16.7 nmol/L for the entire group. 0.17 g/kg/day. Causes of ESRD are shown in Table 1 . Figure 1 shows the distribution of serum P-5Ј-P in our Demographic parameters for the two subgroups followunsupplemented patients at study entry. After 12 months ing randomization for intravenous folic acid are also of supplementation with DiaVite, the median was inpresented in Table 1. creased to 106.6 nmol/L, and only 5 patients had P-5Ј-P After 6 months, 28 patients (17%) were lost at followvalues below the lower normal limit (suggesting either poor absorption and/or compliance). up for the following reasons: death (N ϭ 12), switch At baseline, tHcy serum concentrations were above serum tHcy was normalized in only four patients at 6 months and in four patients at 12 months (only 1 patient normal values in all our patients (100%), ranging from 12.01 to 158 mol/L (mean of 33.3 Ϯ 16.6 mol/L and included at both times), of whom seven (over 8) were receiving intravenous folic acid. There was no further median of 29.7 mol/L). Despite an observed tendency, there was no significant negative correlation between significant decrease in tHcy at 12 months (with or without folic acid). Figure 3 presents serial tHcy serum conceninitial tHcy and serum folate concentrations in our unsupplemented hemodialysis patients (Fig. 2) . After 6 trations (at time 0, 6, and 12 months) for the 128 patients remaining in the study at 12 months. months of supplementation with DiaVite, tHcy serum concentrations decreased significantly to a mean of The distribution of MTHFR genotypes obtained for 161 of the involved hemodialysis patients was as follows: 23.5 Ϯ 7.6 mol/L for the remaining 140 patients (P Ͻ 0.0001). In addition, the mean reduction in tHcy tended 68 patients (42%) had no mutation (CC); 67 (42%) were heterozygotes (CT), and 26 (16%) were homozygotes to be higher in the subgroup also receiving intravenous folic acid, but the difference did not reach significance.
(TT). Among CC, 35 were randomized to intravenous folic acid, among CT, 34, and finally, among TT, 13 We found a mean reduction of tHcy of 12.2 Ϯ 18.5 mol/L for those supplemented with intravenous folic patients. Baseline tHcy, as well as changes in tHcy values, was found to be slightly different in the subgroup analysis acid as a group compared with 8.1 Ϯ 9.7 mol/L for those without the intravenous supplementation at six by genotypes. Table 3 shows tHcy values at baseline, at 6, and at 12 months for each MTHFR genotype (for months (P Ͻ 0.05). At 12 months, no further difference in tHcy between both subgroups was found. However, patients remaining in the study at 12 months). Hence, House and Donnelly gave a standard multivitamin supgenotypes (21.1 Ϯ 6.9 vs. 21.4 Ϯ 6.1 vs. 22.2 Ϯ 5.9 mol/L) plement daily (Nephro-Vite marketed in Canada as were similar to those found at six months. The evolution DiaVite and containing 1 mg of folic acid) to 11 chronic of tHcy is also presented according to the two arms of hemodialysis patients during three weeks [49]; homocysthe study, with and without intravenous folic acid. The teine levels decreased by more than 20%. Dierkes et al addition of folic acid to DiaVite did result in a further recently reported the results of a study comparing 2.5 decrease, although small, in tHcy at six months, particuto 5 mg of folic acid by mouth in hemodialysis and peritolarly in homozygotes for MTHFR in whom the most neal dialysis patients [50]; they found that both supplesignificant impact was observed (P ϭ 0.036; Fig. 4) . mentation regimens reduced homocysteine to the same degree, by nearly 35%. Van Guldener et al measured DISCUSSION homocysteine concentrations in 26 hemodialysis patients randomized to receive either 1 or 5 mg daily by mouth Dialysis patients are at increased risk for deficiencies in hydrosoluble vitamins [25, 46] , since hemodialysis is of folic acid after 52 weeks [41] ; at the end of the study, homocysteine levels did not differ significantly between associated with a relatively high removal rate of watersoluble vitamins. Potential losses are even more proboth groups. The rationale for giving supraphysiologic doses of folic nounced in patients undergoing high-flux or high-efficiency hemodialysis, as shown recently by Kasama et al acid is that it serves as a methyl donor in the remethylation reaction of homocysteine metabolism and is "confor vitamin B 6 [27] . Our results confirm that a significant proportion of chronic hemodialysis patients are deficient sumed" in that reaction. Therefore, by providing a greater amount of folic acid, one can further lower homoin vitamin B 6 if not supplemented (65 patients, or nearly 40%, with overt deficiencies and 61 more patients, or cysteine levels towards normal. Bostom et al have given as much as 15 mg/day of folic acid without side effects 36%, with borderline values, defined as between 11.5 and 25.5 nmol/L). A normal folate status was found in [33] . However, the optimal dose of folic acid required to normalize serum homocysteine, or else, that provides almost all of our unsupplemented patients despite substantial folate losses during hemodialysis; however, a the maximal impact on hyperhomocysteinemia remains unknown at this point. During the study, our patients functional deficit was not excluded. Serum vitamin B 12 was normal in all but five patients at baseline. These were all supplemented with an enteral mixture of hydrosoluble vitamins in the form of DiaVite, containing 1 mg results are similar to those of Descombes, Hanck, and Fellay, who found a vitamin B 6 deficiency in up to 89% of folic acid. Since the content of DiaVite in folic acid is relatively small, it was decided to randomize patients of unsupplemented patients, and normal serum folate and vitamin B 12 concentrations in dialysis patients receivto receive an additional amount of 10 mg intravenous of folic acid at each dialysis session (or 30 mg/week). gotes (TT) presented the highest tHcy concentrations at baseline, as well as the greater reduction in tHcy levels Such a regimen was considered practical from a clinical trial standpoint. After one year of this regimen, respecas a group (41.2%), but nevertheless ended up after 12 months with final tHcy values similar to the patients with tive reductions of 37.5 and 31.8% in serum tHcy concentrations compared with baseline values were observed either normal (CC) or heterozygous (CT) genotypes. Many nonrenal-failure individuals homozygous for the in patients receiving and not receiving intravenous folic acid. Therefore, although present, the effect of the addi-MTHFR mutation have normal serum homocysteine levels; it has been proposed that the homozygous genotype tion of folic acid to DiaVite does not seem major.
Besides folic acid, the impact of a supplementation is not necessarily associated with hyperhomocysteinemia except if a concomitant deficiency in folate occurs [43] . with the other B-complex vitamins such as B 6 and B 12 is more difficult to assess. Several clinical trials looking at Thus, individuals homozygous for the mutation may have higher folate requirements for the regulation of plasma the impact of B-complex vitamin supplementation in hyperhomocysteinemic subjects have found that combinhomocysteine. Interestingly, other investigators have shown that the folate status and the MTHFR mutation ing folic acid, vitamin B 6 , and vitamin B 12 may reduce further the homocysteine concentration when compared interact at a much higher folate level in dialysis patients (folate 29.2 ng/mL) when compared with a population with isolated supplementation with folic acid, B 6 , or B 12 [17, 20, 21] . The impact of vitamin B 6 alone (in doses of with normal renal function (folate 6.8 ng/mL) [48] . Even though our patients had a normal folate status at the 10 mg daily of pyridoxine resulting in a 5% homocysteine reduction) appears smaller than that of folic acid alone beginning of the study, those with the homozygous genotype had higher homocysteine values and appeared more (5 mg daily causing 45 to 50% decrease) [20] . Several studies have shown reductions in homocysteine levels of responsive to additional intravenous folic acid after six months. 30 to 50% with various B-complex multivitamin regimens, whereas others have shown similar decreases with To summarize, (1) hyperhomocysteinemia was present in 100% of our 168 chronic hemodialysis patients. (2) folic acid alone. However, most of these trials concerned hyperhomocysteinemic patients not on dialysis. Since
The distribution of their MTHFR genotypes appeared comparable to the one prevailing in the French Canadian hemodialysis patients are not only hyperhomocysteinemic as a group, but also at risk for deficiencies in hydropopulation. (3) Considering the entire unsupplemented group at baseline, nearly 40% of our patients were defisoluble vitamins, it seems even more appropriate to supplement them aggressively. cient in vitamin B 6 . Few of them presented low serum concentrations of vitamin B 12 , and most of them had a A mutation (an alanine-to-valine substitution, T to C) in MTHFR renders it thermolabile and may be associnormal folate status. (4) Supplementation with DiaVite (with or without added intravenous folic acid) has reated with elevated levels of homocysteine [45] . The incidence of the MTHFR mutation genotypes in our hemosulted in very significant tHcy reductions in serum tHcy for all three genotypes (by more than 29% at 6 months dialysis population is very similar to the reported incidence in the general population [45] . We observed and by close to 35% at 12 months). (5) The impact of the proposed supplementation protocol was found after a slightly different degree of reduction of serum homocysteine for the different MTHFR genotypes. Homozy-6 months and was maintained but did not increase further 
